Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
In this proposed study, the investigators will evaluate the safety and efficacy of lipoic
acid in treatment of Amyotrophic lateral sclerosis (ALS). The study will recruit 150 AD
patients, and then these patients will be randomized to lipoic acid group or control group
(75 patients per arm) for 6 courses for about 5 months. Clinical assessment will be done at
screen/baseline, 3th course and 6th course. The specific aims are to compare lipoic acid
versus control on: motor function and disease progression. During the study period, clinical
effect index will be recorded, including bulbar function, motor function, respiratory
function, and safety index including blood and urine routine, liver and kidney function,
coagulation function.
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University